Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.
about
Spatio-temporal simulation of first pass drug perfusion in the liverTime-Resolved Transcriptomics and Constraint-Based Modeling Identify System-Level Metabolic Features and Overexpression Targets to Increase Spiramycin Production in Streptomyces ambofaciensGenome mining of Streptomyces ambofaciens.Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosisNovel Approaches Reveal that Toxoplasma gondii Bradyzoites within Tissue Cysts Are Dynamic and Replicating Entities In VivoPost-PKS tailoring steps of the spiramycin macrolactone ring in Streptomyces ambofaciensEvaluation of Propranolol Effect on Experimental Acute and Chronic Toxoplasmosis Using Quantitative PCR.A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).Sex-Divergent Clinical Outcomes and Precision Medicine: An Important New Role for Institutional Review Boards and Research Ethics Committees.Alterations in soil microbial communities caused by treatments with penicillin or neomycin.Toxoplasma gondii and schizophrenia: a review of published RCTs.Influence of dextrins on the production of spiramycin and impurity components by Streptomyces ambofaciens.Survey on synergism effect of ketotifen in combination with pyrimethamine in treatment of acute murine toxoplasmosis.Diclofenac sex-divergent drug-drug interaction with Sunitinib: pharmacokinetics and tissue distribution in male and female mice.Sunitinib-ibuprofen drug interaction affects the pharmacokinetics and tissue distribution of sunitinib to brain, liver, and kidney in male and female mice differently.Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.Stimulatory Effects of Methyl-β-cyclodextrin on Spiramycin Production and Physical-Chemical Characterization of Nonhost@Guest Complexes
P2860
Q27322901-3A4263B9-3C49-4E64-B564-EBEA702F1C03Q33665576-31831545-113E-4071-80DB-9736563C9185Q34386573-D7E8C648-3A4A-4832-8CAC-F58A8434DD7DQ35687128-1D623FB5-9DB5-4E56-BCF3-C5639E28448AQ36143596-260BBAF9-17E9-4C83-B92C-A24572351267Q37036600-E9724FD8-BFDE-4853-A94A-8BD1C01EA2F1Q37428612-C1640497-AA2D-47AF-A708-F5B51EFB102CQ37594988-C1633B87-B038-4401-A513-AF9CE82FF9F0Q38635940-C5831281-076A-4BFA-9035-3476464BE23AQ38710261-4F79ABA6-1EBE-42E5-9883-8F7CE6140806Q39308979-CD9BAD69-710C-47F0-A72E-C7AB2189E11BQ40087002-B54406EA-6AA2-42F9-9549-FC123562785DQ47117563-234A17E9-9F43-4F27-BAED-7A1CCF4C5DBCQ47831824-B7248320-E7EE-4563-8F7C-590E5A9298DFQ48159588-5E74E581-BBFF-4B42-8001-5363AB2C597EQ48341764-90EDBFB4-3D91-4EF0-85CF-853BF642C1A1Q58904705-9E9A4194-E6E5-441C-B865-876CBEA2AB9D
P2860
Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Significant reduction of brain ...... odel of chronic toxoplasmosis.
@en
type
label
Significant reduction of brain ...... odel of chronic toxoplasmosis.
@en
prefLabel
Significant reduction of brain ...... odel of chronic toxoplasmosis.
@en
P2860
P921
P356
P1476
Significant reduction of brain ...... model of chronic toxoplasmosis
@en
P2093
Joon Wah Mak
Wai Kit Chew
P2860
P304
P356
10.1128/AAC.05183-11
P407
P577
2012-01-23T00:00:00Z